<?xml version="1.0" encoding="UTF-8"?>
<ack id="ack0001">
 <title>ACKNOWLEDGMENTS</title>
 <p>
  <italic>Financial disclosure</italic>:
 </p>
 <p>
  <italic>Conflict of interest statement</italic>: M.K. has received honoraria from Gilead and Alexion. M.K.D. has served as a consultant for Pharmacyclics and Daiichi Sankyo. M.H. has received research support/funding from Takeda Pharmaceutical, Spectrum Pharmaceuticals, and Astellas Pharma; served as a consultant for Janssen R&amp;D and Incyte; and served on the speaker's bureau for Sanofi Genzyme and AstraZeneca. D.W. reports research support from Incyte and consulting fees from FATE. S.H. reports honoraria and travel funding from Pfizer, Novartis, Gilead, Merck, Sanofi, Mallinckrodt, and Janssen. M.-A.P. has received honoraria from Abbvie, Bellicum, Celgene, Bristol-Myers Squibb, Incyte, Kite/Gilead, Merck, Novartis, Nektar Therapeutics, Omeros, and Takeda; has served on data safety and monitoring boards for Cidara Therapeutics, Servier, and Medigene and scientific advisory boards for MolMed and NexImmune; has received research support for clinical trials from Incyte, Kite/Gilead; and Miltenyi Biotec; and serves in a volunteer capacity as a member of the Board of Directors of Be The Match (National Marrow Donor Program), as well as on the CIBMTR Cellular Immunotherapy Data Resource Executive Committee. C.C. reports honoraria/travel funding from Astellas Pharma, Gilead, Merck, and Pfizer. A.W. has received research support from Ansun, WB Tech, Amazon and Allovir, and is a consultant for Kyorin.
 </p>
</ack>
